alzhub.org
Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

Research

28,180 Alzheimer's and dementia studies in plain English, each scored out of 100.

Find studies

Showing 501–525 of 571 studies · free to read · tagged Digital Tools (page 21 of 23) · 28,180 in the whole library · How the 0–100 score works

Download bibliography of the first 500 of these studies, in this order: BibTeX (.bib) · RIS (.ris)

Browse by subject, author or institution

Each number is how many studies that link shows, with your other filters kept.

Subjects

Authors

Names as each record prints them; the same person can appear under two spellings.

Institutions

From OpenAlex; 13,658 studies have no institution on record and are not counted here.

A note on reading research. One study is rarely the final word.

We try to note the size of a study, whether it was in humans or animals, and how early-stage the finding is. If a summary here doesn't make that clear, treat it with extra caution and check the original source.

R WE ready for reimbursement? A round up of developments in real-world evidence relating to health technology assessment: part 19

✓ Peer-reviewed alzhub usefulness score 35 out of 100. Journal of comparative effectiveness research 2025-05-12

In this update, we examine a checklist for real-world evidence use in Medicare drug price negotiations under the Inflation Reduction Act, a review of health technology assessment reassessments across major health technology assessment agencies, and two complementary studies that used natural experiment approaches to explore the relationship between herpes zoster vaccination and reduced dementia risk. 1 key finding →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Characterization of a mouse model overexpressing beta-site APP-cleaving enzyme 2 reveals a new role for BACE2

✓ Peer-reviewed alzhub usefulness score 34 out of 100. Genes, brain, and behavior 2009-09-22

BACE2 is homologous to BACE1, a beta-secretase that is involved in the amyloidogenic pathway of amyloid precursor protein (APP), and maps to the Down syndrome critical region of chromosome 21. 1 key finding →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Evaluating Sociodemographic Bias in an Artificial Intelligence Algorithm to Detect Cognitive Impairment in Electronic Health Records

✓ Peer-reviewed alzhub usefulness score 34 out of 100. Alzheimer s & Dementia 2024-12-01

Our study highlights the potential of Decipher‐AI for screening undiagnosed cognitive impairment in primary care. 3 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Digital Dementia: Smart Technologies, mHealth Applications and IoT Devices, for Dementia-Friendly Environments

✓ Peer-reviewed alzhub usefulness score 34 out of 100. Journal of Sensor and Actuator Networks 2025-11-24

The global increase in dementia cases, which is predicted to exceed 152 million by 2050, poses substantial challenges to healthcare systems and caregiving structures. 5 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Impact of assistive technologies on caregiver burden and perseverance for people with dementia at home

✓ Peer-reviewed alzhub usefulness score 34 out of 100. Health Policy and Technology 2025-11-20

• AT use was limited and AT type used varied by caregiver living arrangement. • Most used ATs: daily living support and risk prevention; risk response least used. • Daily living support ATs linked to fewer care hours. • Risk prevention ATs tied to longer PT, higher CarerQol-7D, and lower SRB scores. • Daily support and risk response ATs most likely to extend PT by over six months. 4 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Identifying natural inhibitors against FUS protein in dementia through machine learning, molecular docking, and dynamics simulation

✓ Peer-reviewed alzhub usefulness score 34 out of 100. Frontiers in Neuroinformatics 2025-02-05

Dementia, a complex and debilitating spectrum of neurodegenerative diseases, presents a profound challenge in the quest for effective treatments. 5 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Enhanced Multi-Model Machine Learning-Based Dementia Detection Using a Data Enrichment Framework: Leveraging the Blessing of Dimensionality

✓ Peer-reviewed alzhub usefulness score 34 out of 100. Bioengineering 2025-05-30

The early diagnosis of dementia, a progressive condition impairing memory, cognition, and functional ability in older adults, is essential for timely intervention and improved patient outcomes. 1 key finding →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

The Effectiveness of the Comprehensive Dementia Prevention App 'MELI'

✓ Peer-reviewed alzhub usefulness score 34 out of 100. Asia-pacific Journal of Convergent Research Interchange 2025-06-27

This study aimed to evaluate the effectiveness of the comprehensive dementia prevention application 'MELI' in enhancing cognitive function and alleviating depressive symptoms among older adults.A total of 50 participants aged 60 and older, enrolled in a dementia prevention program operated in Namdong-gu, Incheon, South Korea, were randomly assigned to either an experimental or a control group, with 25 participants in each. 1 key finding →

Participants: 50 Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Development and usability of the “Cognitive Evergreenland” app to engage individuals at high risk of dementia in lifestyle interventions

✓ Peer-reviewed alzhub usefulness score 34 out of 100. Scientific Reports 2025-03-15

Multidomain lifestyle interventions can improve cognitive function and mobile health technologies can deliver cost-effective interventions. 1 key finding →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Artificial Intelligence in Hospice Dementia care: Perspectives of Hospice Staff and Family Caregivers

✓ Peer-reviewed alzhub usefulness score 34 out of 100. Innovation in Aging 2025-12-01

Artificial intelligence (AI) has gained attention as a tool to support dementia care through efficient and personalized interventions. 5 key findings →

Participants: 19 Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Chronic elevation of S100 beta protein does not alter APP mRNA expression or promote beta-amyloid deposition in the brains of aging transgenic mice

✓ Peer-reviewed alzhub usefulness score 33 out of 100. Brain research 1995-12-01

S100 beta protein, a member of a Ca(2+)-binding protein family present primarily in the nervous system, affects the survival and differentiation of both neurons and glia cells. 2 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Relationship Between Within-Session Digital Motor Skill Acquisition and Alzheimer Disease Risk Factors Among the MindCrowd Cohort: Cross-Sectional Descriptive Study

✓ Peer-reviewed alzhub usefulness score 33 out of 100. JMIR Aging 2025-04-24

Fifty-four participants (~8% response rate) from the MindCrowd web-based cohort (mean age of 62.39 years; 39 females; and 23 APOE ε4 carriers) completed 75 trials of Super G. Results show that Super G performance was significantly associated with each of the targeted risk factors. 5 key findings →

Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

Artificial Intelligence and Personhood in Dementia

✓ Peer-reviewed alzhub usefulness score 33 out of 100. Dementia and Geriatric Cognitive Disorders 2025-08-20

The unprecedented rise of artificial intelligence (AI) in recent times is unparalleled in history.AI 1 seemingly possesses cognitive abilities that hitherto only humans could boast of -reason, an inimitable, embodied, and finite existence. 47Nonetheless, the ubiquitous abilities of AI can help to enhance treatment and care for PLWDs in 48 enabling early diagnosis, continuous monitoring and personalized support. 1 key finding →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Agentic artificial intelligence in cognitive screening: A translational roadmap for dementia care

✓ Peer-reviewed alzhub usefulness score 33 out of 100. Journal of Alzheimer s Disease Reports 2025-01-01

Conventional dementia screening tools, whether paper tests or static artificial intelligence (AI) models, capture only a snapshot of cognition and need to be adminstered periodically. 5 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Reimagining dementia screening: A stakeholder-informed perspective on artificial intelligence, digital biomarkers, and real-world implementation

✓ Peer-reviewed alzhub usefulness score 33 out of 100. Journal of Alzheimer s Disease Reports 2025-01-01

The approval of disease-modifying treatments for Alzheimer's disease demands a rethinking of cognitive screening. 4 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Machine learning–enhanced screening funnel for clinical trials in Alzheimer's disease

✓ Peer-reviewed alzhub usefulness score 33 out of 100. Alzheimer s & Dementia Translational Research & Clinical Interventions 2025-04-01

This approach predicts clinical progression (2-year Clinical Dementia Rating Sum of Boxes change > 1) with an area under the curve of 0.836. 4 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

↑ Change the filters

Where “Free full text” comes from

Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled.

How the 0–100 score works — and why some entries are capped

This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.

  • Journal tier up to 10 pts
  • Journal's citation record up to 4 pts
  • Study design up to 12 pts
  • Strength of evidence up to 5 pts
  • Peer-review validation up to 10 pts
  • How recent up to 5 pts
  • Sample size up to 4 pts
  • Effect reported up to 3 pts
  • Studied in people up to 3 pts
  • Randomised / blinded up to 2 pts
  • Times cited up to 7 pts
  • Citations per year up to 5 pts
  • Impact for its field and year up to 6 pts
  • Cited by studies here up to 6 pts
  • Still being cited up to 4 pts
  • Senior author's track record up to 4 pts
  • Institution's track record up to 3 pts
  • Multi-centre collaboration up to 3 pts
  • Indexed in PubMed up to 2 pts
  • Free to read up to 2 pts

Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.

Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.

We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.

The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.

See the whole rubric drawn out → — four charts covering all 28,180 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.

What this library is — and isn't

This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 28,180 records, built mostly from automated pulls of Europe PMC (61.7% of the library) and OpenAlex (18.1%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.

1,034 records (3.7% of the library) are not peer-reviewed — 962 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.

See the full, machine-readable breakdown of this library's coverage →

Newest studies, as a dated timeline →    Atom feed